Physician profile
Robin R Hamlin
NPI 1457385452
$8,592.18
in general payments reported to CMS, 2019-2025
13 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,643 · 2020: $290 · 2021: $333 · 2022: $487 · 2023: $230 · 2024: $306 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,729.97 | 2019-2022 | |
| Abbvie INC. | $584.51 | 2023-2025 | |
| Merz North America, INC. | $411.00 | 2019-2022 | |
| Mentor Worldwide LLC | $169.43 | 2022 | |
| Sientra, INC. | $134.11 | 2020-2022 | |
| Kci USA, INC. | $130.20 | 2020 | |
| Galderma Laboratories, L.P. | $110.34 | 2019-2023 | |
| Organogenesis INC. | $96.14 | 2022-2025 | Affinity, Via Matrix |
| Revance Therapeutics, INC. | $75.86 | 2024 | Daxxify |
| Cardiovascular Systems INC. | $53.35 | 2019 | |
| Innovation Technologies INC | $44.79 | 2025 | Irrisept |
| Convatec INC. | $36.12 | 2025 | |
| Olympus America INC. | $16.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hamlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.